LOGIN
Methylene Blue for the Treatment of Lumbar Facet Joint Syndrome
February 2022
Methylene Blue for the Treatment of Lumbar Facet Joint Syndrome
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
Clinical Effects and Safety of the Use of Methylene Blue for the Treatment of Lumbar Facet Joint Syndrome.
Pain Physician. 2022 Jan;25(1): E15-E26.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
One hundred and twenty patients with lumbar facet joint syndrome due to osteoarthritis were randomized to receive an ultrasound-guided intra-articular injection of methylene blue (n=60) or diprospan (n=60). The primary outcome of interest was pain on a Numeric Rating Scale (NRS), measured up to 6 months post-operation. Secondary outcomes of interest included lumbar function, sleep quality, depress...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.